Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE)
SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
Sponsor: Peregrine Pharmaceuticals
Listed as NCT01999673, this PHASE3 trial focuses on Carcinoma, Non-Small-Cell Lung and Non-Small Cell Lung Cancer and remains completed. Sponsored by Peregrine Pharmaceuticals, it has been updated 10 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Mar 2017 — May 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peregrine Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Abilene, United States , Albuquerque, United States , Antwerp, Belgium , Athens, Greece , Athens, United States , Aviano, Italy , Badalona, Spain , Baltimore, United States , Barcelona, Spain and 129 more locations